Navigation Links
Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
Date:6/11/2008

BELLEVUE, WA, June 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX: ONY) (the "Company") today announced that the first patient has been treated in a Phase 1b clinical trial of PX-12 in patients with advanced metastatic cancer. PX-12 is a proprietary small molecule inhibitor of thioredoxin, a protein that regulates diverse molecular pathways that contribute to the growth, survival and drug resistance of many cancers.

The primary objective of the Phase 1b dose-escalation trial is to determine the safety and tolerability of a 72-hour continuous infusion of PX-12 given on the first three days of a 21-day cycle. Other objectives of the trial include an evaluation of the pharmacokinetics and pharmacodynamics of the prolonged infusion, together with identification of any anti-tumor activity. The trial is expected to enroll up to 28 patients at three centers in the United States.

About PX-12

PX-12 is a small molecule designed to inhibit thioredoxin-1. Increased levels of thioredoxin-1 have been noted in many types of cancer cells, including hepatoma, lung cancers, squamous cervical carcinoma, primary gastric cancers and colorectal carcinomas. Increased levels of thioredoxin-1 are associated with decreased sensitivity to a variety of common chemotherapy agents and may cause or contribute to drug resistance.

An initial Phase 1 trial of PX-12 in 38 patients with advanced metastatic cancer showed that PX-12 was well tolerated and produced a decrease in plasma concentrations of thioredoxin that was significantly correlated with increased patient survival. Fifteen of the 38 patients achieved stable disease of up to 322 days. Oncothyreon is also currently conducting a Phase 2 trial of PX-12 given as a 3-hour infusion daily for five days of a 21-day cycle in patients with advanced pancreatic cancer who have progressed on gemcitabine or a gemcitabine-containing regimen.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to the therapeutic and commercial potential of PX-12; future clinical development plans; the details of clinical trials; and the anticipated future size of the market for PX-12. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-12. There can be no guarantee that the results of earlier trials will be predictive of either safety or efficacy in future trials. These and other risks and uncertainties are described in the reports and other documents filed by Oncothyreon Inc. with the SEC and/or Canadian regulatory authorities.

Although Oncothyreon believes that any forward-looking statements contained herein are reasonable, it can give no assurance that its expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of the risks and uncertainties associated with Oncothyreon, you are encouraged to review the official corporate documents filed by Oncothyreon Inc. with the securities regulators in United States and Canada with the SEC and on SEDAR. Oncothyreon is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Additional Information

Additional information relating to Oncothyreon can be found on U.S. EDGAR at http://www.sec.gov and on SEDAR at http://www.sedar.com.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to receive milestone payment
2. Oncothyreon Reports First Quarter 2008 Financial Results
3. Oncothyreon files investigational new drug application for PX-866 oncology compound
4. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
5. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
6. Oncothyreon announces effectiveness of shelf registration statement
7. Oncothyreon announces issuance of patent for PX-867
8. Oncothyreon to present at upcoming investment conferences
9. Oncothyreon reports full year and fourth quarter 2007 financial results
10. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
11. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Meister Media Worldwide ... fresh look and added functionality give the agricultural world a taste of Meister ... shift in agriculture – from precision farming via satellites and Unmanned Aerial Vehicles ...
(Date:4/29/2016)... ... 2016 , ... The MIT bioLogic design team has won multiple A' ... properties can be applied to fabric and formed into living interfaces between body and ... humidity change. The team harvested Natto cells and applied them to fabric with custom ...
(Date:4/29/2016)... 29, 2016 According to ... Research "Separation Systems for Commercial Biotechnology Market - ... Forecast 2015 - 2023", the separation systems for ... Mn in 2014 and is projected to expand ... 2023 to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that the two-level ... sale in the United States. These components expand the capabilities of the system ... sales beginning in October of 2015, the company has seen significant sales growth in ...
Breaking Biology Technology:
(Date:3/17/2016)... LONDON , March 17, 2016 ... market intelligence, forecasts the global biometrics market will ... an impressive 118% increase from 2015. Consumer electronics, ... with embedded fingerprint sensors anticipated to reach two ... Dimitrios Pavlakis , Research Analyst ...
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
Breaking Biology News(10 mins):